CHE
Chemed Corporation NYSE$422.16
Mkt Cap $6.1B
52w Low $365.21
26.0% of range
52w High $583.96
50d MA $401.93
200d MA $432.87
P/E (TTM)
22.9x
EV/EBITDA
14.8x
P/B
6.2x
Debt/Equity
0.2x
ROE
30.6%
P/FCF
18.9x
RSI (14)
—
ATR (14)
—
Beta
0.48
50d MA
$401.93
200d MA
$432.87
Avg Volume
311.6K
About
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in two segments, VITAS and Roto-Rooter. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commerc…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 23, 2026 | AMC | 5.30 | 5.65 | +6.6% | 382.97 | +16.1% | +10.0% | +10.4% | +10.0% | +10.7% | +11.0% | — | — |
| Feb 25, 2026 | AMC | 7.02 | 6.42 | -8.5% | 466.60 | -14.1% | -15.0% | -12.1% | -9.7% | -9.1% | -11.9% | -21.0% | — |
| Oct 28, 2025 | AMC | 5.39 | 5.27 | -2.2% | 438.94 | -1.6% | +6.1% | +3.5% | -1.7% | +0.4% | +0.0% | +0.1% | — |
| Jul 29, 2025 | AMC | 4.78 | 4.27 | -10.7% | 464.69 | -9.7% | -10.4% | -11.3% | -10.1% | -8.9% | -7.9% | -2.8% | — |
| Apr 23, 2025 | AMC | 5.55 | 5.63 | +1.4% | 585.46 | -3.6% | -6.6% | -5.1% | -3.3% | -1.8% | -0.7% | -2.7% | — |
| Feb 26, 2025 | AMC | 6.78 | 6.83 | +0.7% | 545.79 | +4.2% | +7.4% | +10.1% | +8.3% | +7.7% | +9.1% | +11.0% | — |
| Oct 29, 2024 | AMC | 5.76 | 5.64 | -2.1% | 609.80 | -2.4% | -12.1% | -11.4% | -12.8% | -13.9% | -12.6% | -6.1% | — |
| Jul 24, 2024 | AMC | 5.59 | 5.47 | -2.1% | 547.48 | -2.3% | -1.2% | +0.3% | +1.3% | +3.4% | +4.1% | +4.5% | — |
| Apr 24, 2024 | AMC | 5.48 | 5.20 | -5.1% | 617.95 | -4.0% | -7.2% | -9.3% | -8.3% | -8.1% | -8.4% | -10.1% | — |
| Feb 27, 2024 | AMC | 6.25 | 6.60 | +5.6% | 596.60 | +3.1% | +5.4% | +4.9% | +2.9% | +5.9% | +6.7% | +7.6% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 27 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $421.11 | $420.99 | -0.0% | +0.4% | -0.0% | +0.7% | +0.9% | +0.2% |
| Feb 27 | RBC Capital | Downgrade | Outperform → Sector Perform | — | $396.63 | $394.15 | -0.6% | +3.4% | +6.2% | +6.9% | +3.6% | +3.9% |
| Feb 27 | Oppenheimer | Maintains | Outperform → Outperform | — | $396.63 | $394.15 | -0.6% | +3.4% | +6.2% | +6.9% | +3.6% | +3.9% |
| Jan 22 | Jefferies | Downgrade | Buy → Hold | — | $453.53 | $448.68 | -1.1% | -1.9% | -1.5% | -1.2% | -3.7% | -4.6% |
| Nov 10 | RBC Capital | Maintains | Outperform → Outperform | — | $434.61 | $435.00 | +0.1% | +0.3% | +2.5% | +3.0% | +2.6% | +0.2% |
| Sep 10 | BofA Securities | Maintains | Buy → Buy | — | $462.75 | $455.01 | -1.7% | -2.6% | -1.1% | -3.5% | -4.4% | -3.3% |
| Sep 2 | Jefferies | Upgrade | Hold → Buy | — | $457.95 | $470.49 | +2.7% | +1.3% | +0.4% | +0.4% | +1.7% | +1.3% |
| Jul 31 | RBC Capital | Maintains | Outperform → Outperform | — | $416.57 | $412.80 | -0.9% | -1.0% | +0.3% | +1.6% | +2.8% | +3.0% |
| Jul 31 | Oppenheimer | Maintains | Outperform → Outperform | — | $416.57 | $412.80 | -0.9% | -1.0% | +0.3% | +1.6% | +2.8% | +3.0% |
| Jun 30 | BofA Securities | Maintains | Buy → Buy | — | $559.36 | $506.52 | -9.4% | -12.9% | -13.5% | -15.8% | -15.4% | -17.6% |
Recent Filings
8-K
Chemed Corporation -- 8-K Filing
Chemed's Q1 2026 revenue grew from combined 2.2% increase in days-of-care and 2.6% Medicare reimbursement rate gains, supporting continued operational momentum in its home healthcare segment.
Apr 23
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
Chemed refinanced its credit facility, potentially improving borrowing terms and financial flexibility, which could enhance profitability and support growth investments for investors.
Apr 13
8-K
Chemed Corporation -- 8-K Filing
Chemed's revenue growth was driven by higher Medicare reimbursement rates and increased patient days, though unfavorable acuity mix shifts partially offset these gains.
Feb 25
Data updated apr 25, 2026 1:07am
· Source: massive.com